Orexo licenses respiratory program to AstraZeneca

01/29/2013 | PharmaTimes (U.K.)

Sweden's Orexo granted AstraZeneca the right to carry out further preclinical work and evaluation of compounds in its OX-CLI program targeted for respiratory diseases. AstraZeneca was also given the option to purchase the compounds in the program. The deal entitles Orexo to possible milestone fees and royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ